FindTrial
Sign In

Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertension

-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221566
Enrollment
Unknown
Registered
2011-09-06
Start date
2011-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : TAK-536CCB INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material :

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Main inclusion criteria: 1. Grade I or II essential hypertension.

Exclusion criteria

Exclusion criteria: Main exclusion criteria: 1.Secondary hypertension, grade III hypertension, or malignant hypertension 2.Heart disease, cerebrovascular disease, vascular disease, or advanced hypertensive retinopathy 3.Hyperkalemia,etc

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026